Fawcett, legislative director for Results, said the U.S. Lantos-Hyde Act of 2008 called for a bold plan to treat 4.5 million new TB patients and 90,000 patients with multidrug-resistant TB in a span of five years. But the GHI has “curtailed” these goals to only 2.6 million new TB patients and 57,000 patients with MDR in six years’ time.
At current funding levels, and with President Barack Obama’s proposed budget for 2013 cutting some $18 million for TB, Fawcett says it is “unlikely” for the United States to meet even the GHI’s reduced goals. The cutbacks also impede progress in the development of new vaccines, tests and other TB-related services.
TB is a curable disease. Despite this, it claims 1.45 million lives every year and is the second-largest infectious killer of adults. It is also the leading killer of people with HIV and AIDS.
Read more news about development aid online, and subscribe to The Development Newswire to receive top international development headlines from the world’s leading donors, news sources and opinion leaders — emailed to you FREE every business day.